Bioventus (BVS) Stock Price, News & Analysis

Company Overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $7.09 to $7.30
• 50-Day Range: N/A
• 52-Week Range: $5.81 to $14.38
• Volume: 197,273 shs
• Average Volume: 430,249 shs
• Market Capitalization: $594.46 million
• P/E Ratio: 14.08
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BVS Stock Analysis - Frequently Asked Questions

How have BVS shares performed this year?

Bioventus' stock was trading at $6.26 at the start of the year. Since then, BVS shares have increased by 14.9% and is now trading at $7.19.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NASDAQ:BVS) posted its quarterly earnings results on Wednesday, August, 6th. The company reported $0.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. Bioventus had a positive trailing twelve-month return on equity of 23.04% and a negative net margin of 0.03%.

When did Bioventus IPO?

Bioventus (BVS) raised $126 million in an IPO on Thursday, February 11th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity served as the underwriters for the IPO.

How do I buy shares of Bioventus?

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BVS
• Previous Symbol: NASDAQ:BVS
• CIK: 1665988
• Web: N/A
• Phone: (919) 474-6700
• Fax: N/A
• Employees: 1,200
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 14.08
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.54 million
• Net Margins: -0.03%
• Pretax Margin: 0.85%
• Return on Equity: 23.04%
• Return on Assets: 6.04%

Debt

• Debt-to-Equity Ratio: 1.48
• Current Ratio: 1.48
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $564.14 million
• Price / Sales: 1.05
• Cash Flow: $1.08 per share
• Price / Cash Flow: 6.64
• Book Value: $2.28 per share
• Price / Book: 3.15

Miscellaneous

• Outstanding Shares: 82,679,000
• Free Float: 55,395,000
• Market Cap: $594.46 million
• Optionable: N/A
• Beta: 0.84